- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02399215
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVES:
I. To assess progression free survival (PFS), defined as the time interval from initiation of therapy, to its cessation for documentation of progressive disease (PD) or death.
SECONDARY OBJECTIVES:
I. To assess the clinical response (complete response + partial response) in all patients with measurable disease (using standard Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1 criteria).
II. To assess overall survival (OS) in all patients. III. Assess changes in quality of life (QOL) throughout treatment using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) - Gastrointestinal Neuroendocrine Tumors (NET) 21 (GI.NET21) questionnaire for carcinoid patients with gastrointestinal neuroendocrine tumors, in all patients who have filled out at least two QOL questionnaires and, will be reported by groups based on response (response, stable disease or progressive disease).
IV. Steady-state pharmacokinetics (PK) of nintedanib, biomarkers, regulatory T cell (Treg) and cytokine expression and growth factors will be analyzed for all patients and reported in groups based on response.
V. Gene mutations and copy number alterations analysis in the mammalian target of rapamycin (mTOR) pathway (will be performed only on the first 10 patients), protein expression of activation of protein kinase B (Akt) (as well as other downstream targets).
VI. Toxicity (graded using the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4.0) will be closely monitored and all toxicities will be tabulated.
OUTLINE:
Patients receive nintedanib orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 3 months for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient must be on a stable dose of octreotide (Sandostatin®) long-acting release (LAR) or lanreotide for 3 months prior to study enrollment
- Patient must have histologically or cytologically confirmed well differentiated or moderately differentiated (low grade or intermediate grade) neuroendocrine tumor that is locally advanced or metastatic and not of pancreatic origin
- Measurable disease determined by computed tomography (CT) or magnetic resonance imaging (MRI)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Life expectancy greater than 3 months
- Leukocytes >= 3,000/uL
- Absolute neutrophil count >= 1,500/uL
- Total bilirubin =< 2 mg/dL
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x upper limit of normal (ULN) and bilirubin =< ULN for patients without liver metastases
- AST/ALT =< 2.5 x ULN and bilirubin =< ULN for patients with liver metastases
- Patients with Gilbert syndrome and bilirubin < 2 x ULN and normal AST/ALT
- Creatinine =< 1.5 mg/dl
- Prior treatment will be permitted including surgery (>= 4 weeks), cytotoxic chemotherapy (maximum of 2 prior regimens); radiation, interferon, targeted growth factors (>= 4 weeks); and prior treatment with octreotide, will be allowed
- Ability to swallow and retain oral medication
- Participants of child-bearing potential (both male and female) must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
- Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
- Archival tissue of carcinoid biopsy must be available
Exclusion Criteria:
- Uncontrolled hypertension, unstable angina, New York Heart Association grade II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication, or clinically significant peripheral vascular disease (grade II or greater)
- Presence of brain metastases
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, or anticipated need for major surgical procedure during the course of the study, or fine needle aspirations or core biopsies within 7 days prior to day 0
- Significant proteinuria at baseline (>= 500 mg/24 hours [h])
- Serious non-healing wound, ulcer or bone fracture
- Evidence of bleeding diathesis or coagulopathy
- Recent (=< 6 months) arterial thromboembolic events, including transient ischemic attack, cerebrovascular accident, unstable angina, or myocardial infarction
- Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma
- Hepatic artery embolization or ablation of hepatic metastasis within 3 months of enrollment, prior peptide receptor radionuclide therapy (PRRT) within 4 months or any other cancer therapy within 4 weeks (as long as all toxicities are resolved)
- Intolerance or hypersensitivity to octreotide
- Severe or uncontrolled medical conditions
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or nursing female participants
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (nintedanib)
Patients receive nintedanib PO BID on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Ancillary studies
Other Names:
Correlative studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: Time interval from initiation of therapy, to its cessation for documentation of PD or death, assessed up to 2 years
|
Will be reported using standard Kaplan-Meier methods.
Ninety percent confidence intervals for the median PFS will be calculated using Greenwood's formula.
Additionally, a confidence interval for the 16-week PFS rate will be obtained using Jeffrey's prior method.
The association between survival and quantified variables will be investigated using the Cox-proportional hazard model.
|
Time interval from initiation of therapy, to its cessation for documentation of PD or death, assessed up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life Score
Time Frame: Baseline to 30 days post-treatment
|
Quality of life will be investigated calculated by Subjects filing out EORTC Gastrointestinal Neuroendocrine Tumour 21 Questionnaire (QLQ-GI.NET21) A 21 question questionnaire that use a 4-point scale (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). The scores for different scales (i.e. endocrine, gastrointestinal, treatment, social function, disease Related, and global) are calculated by summing related questions from the questionnaire. The range of the subscale scores are from 0 to 100, with higher scores being worse. After the subscale scores being calculated, the Change in quality of life is calculated by subtracting baseline score from end of treatment |
Baseline to 30 days post-treatment
|
Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline and Week 8
Time Frame: Baseline to week 8
|
Sample collection will be obtained at baseline and week 8
|
Baseline to week 8
|
Clinical Response (Complete Response + Partial Response) Measured Using Standard RECISTv1.1 Criteria
Time Frame: Up to 2 years
|
Exact 90% confidence interval estimates using the Clopper-Pearson method will be given for the response rates.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI, response rates are categorized as Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
Up to 2 years
|
Median OS
Time Frame: Up to 3 years (telephone contact is acceptable).
|
Will be reported using standard Kaplan-Meier methods.
Ninety-five percent confidence intervals for the median OS will be calculated using Greenwood's formula.
The association between survival and quantified variables will be investigated using the Cox-proportional hazard model.
|
Up to 3 years (telephone contact is acceptable).
|
Ratio of FGFR IIIb/IIIc and Ki-67 and Microvessel Density Scores
Time Frame: Baseline
|
Scores will be obtained to investigate association with PFS, clinical response, QOL and survival.
|
Baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarker Levels
Time Frame: Baseline
|
Will be analyzed for all patients and reported in groups based on response.
|
Baseline
|
Change in Cytokine Expression
Time Frame: Baseline to 8 weeks
|
Will be analyzed for all patients and reported in groups based on response.
Changes in pre- and post-treatment cytokine expression will be analyzed using permutation paired t-tests.
|
Baseline to 8 weeks
|
Change in Growth Factors
Time Frame: Baseline to 30 days post-treatment
|
Will be analyzed for all patients and reported in groups based on response.
Changes in pre- and post-treatment growth factors will be analyzed using permutation paired t-tests.
|
Baseline to 30 days post-treatment
|
Gene Mutations and Copy Number Alterations
Time Frame: Baseline
|
Gene mutations and copy number alterations in the several pathways particularly mTOR pathway will be evaluated.
Will be analyzed for all patients and correlated with clinical outcomes.
|
Baseline
|
Treg Levels
Time Frame: Baseline
|
Will be analyzed for all patients and reported in groups based on response.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Renuka Iyer, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplasms
- Neuroendocrine Tumors
- Carcinoid Tumor
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Nintedanib
- Tyrosine Protein Kinase Inhibitors
Other Study ID Numbers
- I 259114 (Other Identifier: Roswell Park Cancer Institute)
- NCI-2015-00238 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoid Tumor
-
National Cancer Institute (NCI)CompletedMetastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Regional Gastrointestinal Carcinoid TumorUnited States
-
Crinetics Pharmaceuticals Inc.Active, not recruitingCarcinoid Tumor | Carcinoid Syndrome | Carcinoid | Carcinoid Tumor of Ileum | Carcinoid Tumor of Cecum | Carcinoid Syndrome Diarrhea | Carcinoid Intestine Tumor | Carcinoid Tumor of Liver | Carcinoid Tumor of PancreasUnited States, Brazil, Argentina, Canada, Mexico, Peru, Poland
-
Roswell Park Cancer InstituteNeuroEndocrine Tumor Research Foundation (NETRF)RecruitingLung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid TumorUnited States
-
M.D. Anderson Cancer CenterRecruitingCarcinoid Tumor | Carcinoid Syndrome | Metastatic Carcinoid Tumor | Digestive System Neuroendocrine Tumor G1United States
-
National Cancer Institute (NCI)TerminatedGastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Regional Gastrointestinal Carcinoid Tumor | Pulmonary Carcinoid TumorUnited States
-
National Cancer Institute (NCI)CompletedMetastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid TumorCanada
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedGastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Pulmonary Carcinoid TumorUnited States
-
Mid-Atlantic Oncology ProgramCancer Biotherapy Research GroupCompletedLung Cancer | Gastrointestinal Carcinoid TumorUnited States
-
Molecular Insight Pharmaceuticals, Inc.Withdrawn
-
Massachusetts General HospitalWithdrawnSmall Bowel Carcinoid TumorUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States